Recent studies of the tumor genome seek to identify cancer pathways as groups of genes in
which mutations are epistatic with one another or, specifically," mutually exclusive." Here, we …

Translating data to knowledge and actionable insights is the Holy Grail for many scientific
fields, including biology. The unprecedented massive and heterogeneous data have created …

Genetic redundancy has evolved as a way for human cells to survive the loss of genes that
are single copy and essential in other organisms, but also allows tumours to survive despite …

While synthetic lethality (SL) holds promise in developing effective cancer therapies, SL
candidates found via experimental screens often have limited translational value. Here we …

Motivation A synthetic lethal (SL) interaction is a relationship between two functional entities
where the loss of either one of the entities is viable but the loss of both entities is lethal to the …

Synthetic lethality (SL) occurs when the inactivation of two genes results in cell death while
the inactivation of either gene alone is non-lethal. SL-based therapy has become a …

Somatically acquired genomic alterations that drive oncogenic cellular processes are of
great scientific and clinical interest. Since the initiation of large-scale cancer genomic …

Synthetic dosage lethality (SDL) denotes a genetic interaction between two genes whereby
the underexpression of gene A combined with the overexpression of gene B is lethal. SDLs …

Targeted therapies rely on the genetic and epigenetic status of the tumor cells and are seen
as the most promising approach to treat cancer today. However, current targeted therapies …

Poly (ADP-ribose) polymerase 1 inhibitors (PARPi) are used to treat recurrent ovarian
cancer (OC) patients due to greater survival benefits and minimal side effects, especially in …